Top

Acta Neurochirurgica

Published in:

Open Access 01-03-2022 | Glioma | Original Article - Brain Tumors

Pretreatment patient-reported cognitive function in patients with diffuse glioma

Authors: Stine Schei, Ole Solheim, Øyvind Salvesen, Marianne Jensen Hjermstad, David Bouget, Lisa Millgård Sagberg

Published in: Acta Neurochirurgica | Issue 3/2022

Abstract

Purpose

Cognitive function is frequently assessed with objective neuropsychological tests, but patient-reported cognitive function is less explored. We aimed to investigate the preoperative prevalence of patient-reported cognitive impairment in patients with diffuse glioma compared to a matched reference group and explore associated factors.

Methods

We included 237 patients with diffuse glioma and 474 age- and gender-matched controls from the general population. Patient-reported cognitive function was measured using the cognitive function subscale in the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. The transformed scale score (0–100) was dichotomized, with a score of ≤ 75 indicating clinically important patient-reported cognitive impairment. Factors associated with preoperative patient-reported cognitive impairment were explored in a multivariable regression analysis.

Results

Cognitive impairment was reported by 49.8% of the diffuse glioma patients and by 23.4% in the age- and gender-matched reference group (p < 0.001). Patients with diffuse glioma had 3.2 times higher odds (95% CI 2.29, 4.58, p < 0.001) for patient-reported cognitive impairment compared to the matched reference group. In the multivariable analysis, large tumor volume, left tumor lateralization, and low Karnofsky Performance Status score were found to be independent predictors for preoperative patient-reported cognitive impairment.

Conclusions

Our findings demonstrate that patient-reported cognitive impairment is a common symptom in patients with diffuse glioma pretreatment, especially in patients with large tumor volumes, left tumor lateralization, and low functional levels. Patient-reported cognitive function may provide important information about patients’ subjective cognitive health and disease status and may serve as a complement to or as a screening variable for subsequent objective testing.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: J Natl Cancer Inst 85:365–376. https://doi.org/10.1093/jnci/85.5.365

Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG (2013) Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31:4076. https://doi.org/10.1200/JCO.2013.49.6067CrossRefPubMedPubMedCentral

Boele FW, Zant M, Heine ECE, Aaronson NK, Taphoorn MJB, Reijneveld JC, Postma TJ, Heimans JJ, Klein M (2014) The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neuro-Oncology Practice 1:40–46. https://doi.org/10.1093/nop/npu007CrossRefPubMedPubMedCentral

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary J-P, Hadjipanayis CG, Urbanic JJ, Barker FG, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049–1060. https://doi.org/10.1016/S1470-2045(17)30441-2CrossRefPubMedPubMedCentral

Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA, Oncology fN, (2020) Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38:1019–1029. https://doi.org/10.1200/jco.19.02767CrossRefPubMedPubMedCentral

Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC (2020) Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. Eur J Cancer 144:162–168. https://doi.org/10.1016/j.ejca.2020.10.040CrossRefPubMed

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8CrossRefPubMed

Cheng J-x, Liu B-l, Zhang X, Lin W, Zhang Y-q, Liu W-p, Zhang J-n, Lin H, Wang R, Yin H (2010) Health-related quality of life in glioma patients in China. BMC Cancer 10:1–8. https://doi.org/10.1186/1471-2407-10-305CrossRef

Chow TW (2000) Personality in frontal lobe disorders. Curr Psychiatry Rep 2:446–451. https://doi.org/10.1007/s11920-000-0031-5CrossRefPubMedPubMedCentral

10.

Cochereau J, Herbet G, Duffau H (2016) Patients with incidental WHO grade II glioma frequently suffer from neuropsychological disturbances. Acta Neurochir (Wien) 158:305–312. https://doi.org/10.1007/s00701-015-2674-3CrossRef

11.

Coomans M, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T (2019) The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. Eur J Cancer 116:190–198. https://doi.org/10.1016/j.ejca.2019.05.012CrossRefPubMed

12.

Drewes C, Sagberg LM, Jakola AS, Gulati S, Solheim O (2015) Morbidity after intracranial tumor surgery: sensitivity and specificity of retrospective review of medical records compared with patient-reported outcomes at 30 days. J Neurosurg 123:972–977. https://doi.org/10.3171/2014.12.JNS142206CrossRefPubMed

13.

Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring manual, 3rd edn. European Organisation for Research and Treatment og Cancer, Brussels

14.

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J-C, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R (2012) 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 30:1323–1341. https://doi.org/10.1016/j.mri.2012.05.001CrossRefPubMedPubMedCentral

15.

Fosså SD, Lothe Hess S, Dahl AA, Hjermstad MJ, Veenstra M (2007) Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol 46:452–461. https://doi.org/10.1080/02841860601182641CrossRefPubMed

16.

Fox SW, Lyon D, Farace E (2007) Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 39:61–67CrossRefPubMed

17.

Froklage FE, Oosterbaan LJ, Sizoo EM, de Groot M, Bosma I, Sanchez E, Douw L, Heimans J, Reijneveld J, Lagerwaard F (2014) Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. J Neurooncol 116:387–394CrossRefPubMed

18.

Gehring K, Taphoorn MJB, Sitskoorn MM, Aaronson NK (2015) Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. Neuro-oncology practice 2:20–31. https://doi.org/10.1093/nop/npu035CrossRefPubMedPubMedCentral

19.

Gempt J, Lange N, Bette S, Foreman SC, Cammardella JH, Albertshauser J, Gradtke C, Buchmann N, Ryang Y-M, Schmidt-Graf F (2017) Factors influencing neurocognitive function in patients with neuroepithelial tumors. Sci Rep 7:1–10. https://doi.org/10.1093/neuonc/nox168CrossRef

20.

Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8. https://doi.org/10.1016/j.jclinepi.2019.10.003CrossRefPubMed

21.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573CrossRefPubMedPubMedCentral

22.

Giovagnoli AR, Meneses RF, Paterlini C, Silvani A, Boiardi A (2021) Cognitive awareness after treatment for high-grade glioma. Clin Neurol Neurosurg 210:106953. https://doi.org/10.1016/j.clineuro.2021.106953CrossRefPubMed

23.

Habets EJJ, Kloet A, Walchenbach R, Vecht CJ, Klein M, Taphoorn MJB (2014) Tumour and surgery effects on cognitive functioning in high-grade glioma patients. Acta Neurochir (Wien) 156:1451–1459. https://doi.org/10.1007/s00701-014-2115-8CrossRef

24.

Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. International Journal of Radiation Oncology*Biology*Physics 55:992–999. https://doi.org/10.1016/S0360-3016(02)04205-0

25.

Hendrix P, Hans E, Griessenauer CJ, Simgen A, Oertel J, Karbach J (2017) Neurocognitive status in patients with newly-diagnosed brain tumors in good neurological condition: the impact of tumor type, volume, and location. Clin Neurol Neurosurg 156:55–62. https://doi.org/10.1016/j.clineuro.2017.03.009CrossRefPubMed

26.

Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ= C30 (+ 3). J Clin Oncol 16:1188–1196. https://doi.org/10.1200/JCO.1998.16.3.1188CrossRefPubMed

27.

Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934. https://doi.org/10.1016/j.ctrv.2012.05.002CrossRefPubMed

28.

Johnson DR, Sawyer AM, Meyers CA, O’Neill BP, Wefel JS (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 14:808–816. https://doi.org/10.1093/neuonc/nos082CrossRefPubMedPubMedCentral

29.

Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, Leenstra S, Tulleken CA, Boogerd W, Belderbos JS (2001) Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol 19:4037–4047. https://doi.org/10.1200/JCO.2001.19.20.4037CrossRefPubMed

30.

Klein M, Duffau H, Hamer PCDW (2012) Cognition and resective surgery for diffuse infiltrative glioma: an overview. J Neurooncol 108:309–318. https://doi.org/10.1007/s11060-012-0811-xCrossRefPubMedPubMedCentral

31.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

32.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

33.

Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 53:2002–2007CrossRefPubMed

34.

Noll KR, Ziu M, Weinberg JS, Wefel JS (2016) Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol 128:323–331. https://doi.org/10.1007/s11060-016-2114-0CrossRefPubMedPubMedCentral

35.

Orfei MD, Robinson RG, Prigatano GP, Starkstein S, Rüsch N, Bria P, Caltagirone C, Spalletta G (2007) Anosognosia for hemiplegia after stroke is a multifaceted phenomenon: a systematic review of the literature. Brain 130:3075–3090. https://doi.org/10.1093/brain/awm106CrossRefPubMed

36.

Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology 22:iv1-iv96. https://doi.org/10.1093/neuonc/noaa200

37.

Pranckeviciene A, Deltuva VP, Tamasauskas A, Bunevicius A (2017) Association between psychological distress, subjective cognitive complaints and objective neuropsychological functioning in brain tumor patients. Clin Neurol Neurosurg 163:18–23. https://doi.org/10.1016/j.clineuro.2017.10.007CrossRefPubMed

38.

Schubart JR, Kinzie MB, Farace E (2008) Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol 10:61–72. https://doi.org/10.1215/15228517-2007-040CrossRefPubMedPubMedCentral

39.

Sinha R, Stephenson JM, Price SJ (2020) A systematic review of cognitive function in patients with glioblastoma undergoing surgery. Neuro-Oncology Practice 7:131–142. https://doi.org/10.1093/nop/npz018CrossRefPubMed

40.

Sterckx W, Coolbrandt A, de Casterlé BD, Van den Heede K, Decruyenaere M, Borgenon S, Mees A, Clement P (2013) The impact of a high-grade glioma on everyday life: a systematic review from the patient’s and caregiver’s perspective. Eur J Oncol Nurs 17:107–117CrossRefPubMed

41.

Steward KA, Kretzmer T (2021) Anosognosia in moderate-to-severe traumatic brain injury: a review of prevalence, clinical correlates, and diversity considerations. The Clinical Neuropsychologist. https://doi.org/10.1080/13854046.2021.1967452

42.

Talacchi A, Santini B, Savazzi S, Gerosa M (2011) Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol 103:541–549. https://doi.org/10.1007/s11060-010-0417-0CrossRefPubMed

43.

Tucha O, Smely C, Preier M, Lange KW (2000) Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 47:324–334. https://doi.org/10.1097/00006123-200008000-00011CrossRefPubMed

44.

van der Meer PB, Koekkoek JAF, van den Bent MJ, Dirven L, Taphoorn MJB (2021) Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. J Neurooncol 153:89–98. https://doi.org/10.1007/s11060-021-03747-1CrossRefPubMedPubMedCentral

45.

van Kessel E, Baumfalk AE, van Zandvoort MJ, Robe PA, Snijders TJ (2017) Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment. J Neurooncol 134:9–18. https://doi.org/10.1007/s11060-017-2503-zCrossRefPubMedPubMedCentral

46.

Van Kessel E, Emons MAC, Wajer IH, Van Baarsen KM, Broekman ML, Robe PA, Snijders TJ, Van Zandvoort MJE (2019) Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment. Neuro-Oncology Practice 6:463–472. https://doi.org/10.1093/nop/npz008CrossRefPubMedPubMedCentral

47.

van Kessel E, Wajer IMH, Ruis C, Seute T, Fonville S, De Vos FY, Verhoeff JJ, Robe PA, van Zandvoort MJ, Snijders TJ (2021) Cognitive impairments are independently associated with shorter survival in diffuse glioma patients. J Neurol 268:1434–1442CrossRefPubMed

48.

Zhu J-J, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A, Zvi Ram on behalf of the EFTI (2017) Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 135:545–552. https://doi.org/10.1007/s11060-017-2601-yCrossRef

Title: Pretreatment patient-reported cognitive function in patients with diffuse glioma
Authors: Stine Schei
Ole Solheim
Øyvind Salvesen
Marianne Jensen Hjermstad
David Bouget
Lisa Millgård Sagberg
Publication date: 01-03-2022
Publisher: Springer Vienna
Keywords: Glioma
Glioma
Glioma
Published in: Acta Neurochirurgica / Issue 3/2022
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-022-05126-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pretreatment patient-reported cognitive function in patients with diffuse glioma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2022

Response to: Some historical remarks on ipsilateral hemiparesis and the absence of decussation of the pyramidal tracts

The “springform” technique in cranioplasty: custom made 3D-printed templates for intraoperative modelling of polymethylmethacrylate cranial implants

Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine–based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage

Long-term outcome after severe traumatic brain injury: a systematic literature review

Current decision support tools fail to agree or predict therapeutic decisions in a single cohort of unruptured intracranial aneurysms

How I do it: horizontal fissure approach to the middle cerebellar peduncle